NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04377659 2025-05-28
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04370834 2025-02-04
Tocilizumab for Patients With Cancer and COVID-19 Disease
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed